WideTrial (@WideTrial) header
WideTrial (@WideTrial) profile picture

The only third-party platform for sponsoring #ExpandedAccess clinical programs for new medicines. Leading the way with Real-World treatment outcomes data.

Global
Joined November 2012
Photo by WideTrial (@WideTrial)Photo by WideTrial (@WideTrial)Photo by WideTrial (@WideTrial)Photo by WideTrial (@WideTrial)Photo by WideTrial (@WideTrial)Photo by WideTrial (@WideTrial)Photo by WideTrial (@WideTrial)Photo by WideTrial (@WideTrial)Photo by WideTrial (@WideTrial)
Who decides when a pandemic is over? What we are seeing is a struggle for health equity. Those who are most vulnerable— who, when the next variant strikes, are at highest risk of ending up dead or disabled— are demanding more be done to stop transmission. Stand with them.
114
320
18
1,262
Follow @Expanded_Access now for real time fact checking on #ExpandedAccess to medicines in during Congressional Hearing on #ALS right now, 11am - 1pm Eastern energycommerce.house.gov/com…
Just a few days left of Early Bird registration for the big annual #ExpandedAccess Summit, the global leadership event on pre-market access to medicines. axspharma.com/expanded-acces… #ALS #Cancer #healthcareinnovation
1
1
#ExpandedAccess for patients who cannot get into the research trial was created by FDA 33 years ago as an integral part of the drug development process. But don't take our word for it. axspharma.com/videos/ea3-tra…
Unbelievable... the nerve to say 2030 when Nurown would have been available years ago had it been funded. Yep they had to be funded by the taxpayers of California. Instead of ALS Association. Not to mention we could have had @WideTrial expanded access.
“#MedAffairsTalk - Expanded Access Programs” with @LucaDezzani, @abbyleighfraser, @SBoraErdemli, @MariekeJonkman, @cavemom11, and Pharma Medical Affairs. Friday, Jun 4 at 1:00 PM EDT on @clubhouse! clubhouse.com/event/M65keG9B
1
3
6
The principals of Parallel Track were rolled into the Expanded Access regs now in place, applying to all diseases. What's needed is a public reminder that large-cohort #ExpandedAccess was created for treatment use in parallel with research (not just post-research). Just ask @FDA
Bipartisan "parallel track" support in ALS is real. Reminder: This was 2 YEARS ago: @brainmatters10 @gregggonsalves @WideTrial @iamalsorg #ALS @statnews @medpagetoday #ALSA @BIOGEN @Chance4Lisa @SenatorBraun @SenTedCruz @biospace #ENDALS #ALS NME heartland.org/publications-r…
The principals of Parallel Track were rolled into the Expanded Access regulations now in place, applying to all diseases. What's needed is a public reminder that large-cohort #ExpandedAccess was created for treatment use in parallel with research (not just post-research).
The full video replays of the 2021 Ax-S Thursdays sessions on Integrating Research and Healthcare are now available on our video page in the "free/signup" section for 2 weeks. axspharma.com/video-resource…
2
3
Looking forward to hearing @mikaenewton from xCures present the digital precision-oncology platform tomorrow at #AxSThursdays Join here: pheedloop.com/axsthursdays/s…
Here is the "top-of-the-league" on Decentralized #clinicaltrials . Tomorrow (Thursday) at 12pm-1:30pm Eastern. pheedloop.com/axsthursdays/s…
1
1
Ding, ding, ding In collaboration with Dr. Silverman, we identified the first compound that improves the health of UMNs that become diseased due to mSOD1 toxicity & TDP43 pathology. This is good news for #ALS, #HSP, #PLS, and ALS/FTLD patients. Please RT & share the excitement
18
61
13
200
We have just made this FREE. Next Thursday and the whole series on Expanding Access to new medicines. Learn more and sign up here: axspharma.com/axs-thursdays/… #ExpandedAccess #ClinicalTrials #RealWorldEvidence
1
1
2
3
#ExpandedAccess to new medicines is finally back in focus, tomorrow (Thursday) 2pm Eastern with some very heavy hitters on the broadcast. Sign up here! pheedloop.com/axsthursdays/s…
The Ulixertinib Expanded Access Program for patients with MAPK mutation ... youtu.be/NhOFjKW0_TQ via @YouTube
A 1-minute excerpt from the 15-min case review of Novartis Gleevec #ExpandedAccess program in #Leukemia #Cancer. youtu.be/DVqzdPArat8